- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Kyverna links CAR-T to improved autoimmune outcomes in small trial | 2 | FierceBiotech | ||
| Mi | Positive Studiendaten zu Myasthenia Gravis beflügeln Kyverna-Aktie | 5 | Investing.com Deutsch | ||
| Mi | Kyverna Therapeutics stock surges after positive myasthenia gravis trial data | 1 | Investing.com | ||
| Mi | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 | 263 | GlobeNewswire (Europe) | Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically... ► Artikel lesen | |
| Mi | Kyverna Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.10. | Kyverna Therapeutics stock price target raised to $20 from $10 at H.C. Wainwright | 2 | Investing.com | ||
| KYVERNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.10. | Kyverna's CAR T-cell therapy shows promise in refractory arthritis trial | 5 | Investing.com | ||
| 25.10. | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 | 290 | GlobeNewswire (Europe) | KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate... ► Artikel lesen | |
| 22.10. | Kyverna to present interim KYV-101 phase 2 data for myasthenia gravis | 6 | Investing.com | ||
| 08.10. | Kyverna Therapeutics stock price target raised to $27 at Wells Fargo | 4 | Investing.com | ||
| 08.10. | Wells Fargo hebt Kursziel für Kyverna Therapeutics auf 27 US-Dollar an | 20 | Investing.com Deutsch | ||
| 25.09. | Kyverna Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 2 | Investing.com | ||
| 24.09. | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS | 198 | GlobeNewswire (Europe) | KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101... ► Artikel lesen | |
| 15.09. | Kyverna stellt Phase-2-Daten zu Myasthenia Gravis auf AANEM-Tagung vor | 4 | Investing.com Deutsch | ||
| 15.09. | Kyverna to present phase 2 myasthenia gravis data at AANEM meeting | 1 | Investing.com | ||
| 15.09. | Kyverna Therapeutics, Inc.: Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 | 545 | GlobeNewswire (Europe) | Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up? Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate... ► Artikel lesen | |
| 28.08. | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event | 213 | GlobeNewswire (Europe) | KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase... ► Artikel lesen | |
| 20.08. | Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 | 3 | Benzinga.com | ||
| 20.08. | William Blair initiates coverage on Kyverna Therapeutics stock with Outperform rating | 1 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,65 | +0,50 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CUREVAC | 4,572 | -1,08 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| VALNEVA | 4,012 | -0,20 % | Valneva-Aktie sorgt für Unruhe - Analysten warnen vor einem möglichen Schockstart in die Woche! | ||
| AMGEN | 259,70 | +0,78 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,338 | +0,60 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| STRYKER | 308,10 | -0,36 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen | |
| BIOGEN | 134,75 | +0,60 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| ILLUMINA | 107,18 | -0,24 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | -2,67 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,520 | +1,53 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| INTELLIA THERAPEUTICS | 11,110 | +0,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 78,50 | +0,64 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine |
Das Unternehmen KYVERNA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,970 Euro und damit +3,41 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KYVERNA THERAPEUTICS INC finden Sie auf Wallstreet Online.